Suppliers and packagers for MAVENCLAD

MAVENCLAD

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Emd Serono Inc	MAVENCLAD	cladribine	TABLET;ORAL	022561	NDA	EMD Serono, Inc.	44087-4000-0	5 BLISTER PACK in 1 CARTON (44087-4000-0) / 2 TABLET in 1 BLISTER PACK	2019-04-01
Emd Serono Inc	MAVENCLAD	cladribine	TABLET;ORAL	022561	NDA	EMD Serono, Inc.	44087-4000-4	4 BLISTER PACK in 1 CARTON (44087-4000-4) / 1 TABLET in 1 BLISTER PACK	2019-04-01
Emd Serono Inc	MAVENCLAD	cladribine	TABLET;ORAL	022561	NDA	EMD Serono, Inc.	44087-4000-5	5 BLISTER PACK in 1 CARTON (44087-4000-5) / 1 TABLET in 1 BLISTER PACK	2019-04-01
Emd Serono Inc	MAVENCLAD	cladribine	TABLET;ORAL	022561	NDA	EMD Serono, Inc.	44087-4000-6	6 BLISTER PACK in 1 CARTON (44087-4000-6) / 1 TABLET in 1 BLISTER PACK	2019-04-01

Suppliers for MAVENCLAD (cladribine) 10 mg tablets: API, commercial manufacturing, and key supply-chain risk points

Last updated: May 27, 2026

MAVENCLAD (cladribine tablets) is supplied to the US market by Merck KGaA (product owner) under a complex multi-party manufacturing and distribution network. Key supply constraints for MAVENCLAD are concentrated in (1) sterile-free oral-solid API manufacture, (2) tablet manufacturing and release for the 10 mg strength, and (3) finished-goods distribution tied to country-level marketing authorizations.

Who manufactures the MAVENCLAD API (cladribine) and who are the contract suppliers?

Answer (quick): API supply for cladribine for commercial MAVENCLAD is not a single-source public commodity. The API and finished-dose supply chain typically uses at least one contract manufacturer plus the authorized marketing authorization holder’s global manufacturing network, with country-specific release sites. Public sources that enumerate exact API vendors are limited and not consistently disclosed in US FDA product labeling.

What do MAVENCLAD labels disclose about manufacturing and release sites?

MAVENCLAD US prescribing information identifies manufacturing and packaging responsibilities at the product level (finished dosage form), not always the underlying API vendor. For supply-chain planning, the most reliable public “supplier” disclosures are the finished-goods manufacturer(s) named in FDA labeling and the sites listed in regulatory submissions and marketing authorization dossiers.

How to map API supplier identity from regulatory artifacts

For cladribine-based oral products, API vendor identity can often be inferred from:

• The “manufactured for” and “distributed by” blocks on the US label
• European public assessment reports (where available)
• Site-specific authorizations tied to GMP compliance at the API and finished-dose levels

Because API vendor names are not systematically listed in consumer-facing labeling, business due diligence should focus on FDA/EMA GMP site names and then trace them to upstream API capability through procurement questionnaires and audit reports.

What are the finished-dose “suppliers” for MAVENCLAD 10 mg tablets in the US?

Answer (quick): Finished-dose suppliers are the named manufacturers and packagers on the MAVENCLAD US prescribing information, typically under Merck KGaA’s marketing authorization.

What to check on the label for procurement planning

For operational sourcing, the label blocks that matter are:

• “Manufactured by” and “Packaged by” entities
• “Distributed by” entity and US address
• Country-specific packaging formats that can change over time

These blocks are the most defensible starting point for a contract tender because they are tied to regulatory approval.

What supply constraints are most relevant for a cladribine tablet product?

Oral cytotoxic oncology/neuroimmunology-adjacent agents like cladribine face:

• Demand-sensitive campaign manufacturing
• Regulatory-controlled change management (site transfers require supplemental approvals)
• Short-notice production interruptions due to GMP remediation or sterility-adjacent process controls (even for non-sterile oral products, controlled environments and cleaning validation still drive complexity)

Are there multiple MAVENCLAD tablets suppliers by country (EU vs US vs others)?

Answer (quick): Yes. Finished-dose and packaging supply chains for cladribine tablets are country-specific, reflecting local marketing authorization holder structures and site approvals.

How multi-country authorizations affect supplier switching

Supplier switching triggers:

• GMP release at approved sites
• Batch record compliance for country-specific packaging and labeling
• Device-like packaging formats (blister and carton configs) that can require distinct packaging line qualification

This means a “supplier list” can be different by geography even when the marketing authorization holder is the same.

What Orange Book status applies to MAVENCLAD, and how does that affect supplier competition?

Answer (quick): MAVENCLAD is a branded product with limited generic pathway visibility for cladribine tablets; competition risk is more likely from follow-on entrants rather than direct label-identical generic substitution.

Why patent landscape is a supply-chain factor

If generic entry is constrained by patent coverage, supply competition stays limited to:

• Branded product manufacturing network
• Licensed follow-on supply arrangements
• Parallel import/distribution channels, where allowed

This reduces the practical supplier pool for procurement.

What manufacturing and IP barriers can block alternative cladribine tablet supply?

Answer (quick): Barriers are driven by regulatory site qualification, validated manufacturing processes for cladribine tablets, and patent protection around formulations and/or manufacturing methods.

Key categories of barriers

• GMP site qualification for cytotoxic API handling and dedicated cleaning validation
• Process validation and control strategy for tablet potency and impurity profile
• Regulatory approval for labeling, packaging, and batch release conformity by country

What is the most likely supply-chain structure used for MAVENCLAD?

Answer (quick): A typical structure is:

1. API manufacture at an authorized cladribine GMP site
2. Finished tablet manufacture and packaging at one or more GMP sites
3. Distribution through approved wholesalers to treatment centers and specialty pharmacy networks

In practice, step 2 (finished-dose tablet manufacturing and blister/box packaging) is the operational bottleneck when supply is tight.

Key supply-chain due diligence targets for MAVENCLAD procurement or licensing

Answer (quick): The most decision-relevant checks are:

• Named finished-dose manufacturer(s) on the approved label
• GMP site authorization for that manufacturer for cladribine tablets
• Batch release site(s) and any recent site change supplements
• Historical supply disruptions and remediation events tied to the named sites

Key Takeaways

• MAVENCLAD cladribine tablets have a branded manufacturing network tied to regulator-approved finished-dose sites; public label data usually names finished-dose suppliers more reliably than API vendors.
• Supplier identity is country-specific; procurement and licensing must start with the label’s “manufactured/packaged/distributed” blocks and then map to GMP-authorized sites.
• The practical supplier bottleneck is finished-dose tablet manufacturing and packaging line qualification, not just API capability.
• Patent and regulatory barriers limit generic-style supply substitution, keeping the effective supplier set concentrated in the brand’s authorized network.

FAQs

1) How do I identify the finished-dose manufacturer for MAVENCLAD in the US?

Use the “Manufactured by” and “Packaged by” blocks in the MAVENCLAD US prescribing information and label. Those entities are the legally identified finished-dose suppliers.

2) Who makes cladribine API for MAVENCLAD?

API vendor identity is often not fully disclosed in US label text; the defensible approach is to trace from GMP-authorized sites referenced in regulatory documentation and then confirm via supplier qualification and audit disclosures.

3) Can MAVENCLAD be supplied by multiple manufacturers at the same time?

Yes, when authorized by regulators and when batch release and labeling/packaging formats are maintained. Multi-site capability is common for high-control oral cytotoxic agents.

4) Does MAVENCLAD have generic alternatives that change the supplier landscape?

Direct generic substitutions depend on patent and approval status for cladribine tablets in the relevant jurisdiction; where generics are constrained, supply stays dominated by the branded network.

5) What creates the highest risk for MAVENCLAD supply interruptions?

Finished-dose tablet manufacturing and packaging campaign constraints at GMP sites, plus change-control and site-authorizations that slow switching during disruptions.

References

1. FDA. “MAVENCLAD (cladribine) tablets, prescribing information.” U.S. Food and Drug Administration.
2. EMA. “Assessment report and EPAR for MAVENCLAD (cladribine).” European Medicines Agency.
3. FDA. Orange Book database: MAVENCLAD (cladribine) tablets. U.S. Food and Drug Administration.